The venture was found in North America in United States. The main department of described VC is located in the New York.
We also calculated 3 valuable employees in our database.
The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2019. This Perceptive Advisors works on 28 percentage points more the average amount of lead investments comparing to the other organizations. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies. The typical startup value when the investment from Perceptive Advisors is 100-500 millions dollars. The common things for fund are deals in the range of 50 - 100 millions dollars. The increased amount of exits for fund were in 2018.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Allogene Therapeutics, BridgeBio, Alector. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Genetics, Biopharma.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Perceptive Advisors, startups are often financed by Third Rock Ventures, F-Prime Capital, Morgenthaler Ventures. The meaningful sponsors for the fund in investment in the same round are ArrowMark Partners, RTW Investments LLC, Viking Global Investors. In the next rounds fund is usually obtained by OrbiMed, Pontifax, Warburg Pincus.
Funds with similar focus
|$149M||07 Dec 2022||San Francisco, California, United States|
|$50M||16 Nov 2022||Colorado, United States|
|$118M||07 Nov 2022||-|
|$110M||10 Oct 2022||Germany, Baden-Württemberg, Germany|
|$75M||30 Sep 2022||Marlborough, Massachusetts, United States|
|$225M||07 Sep 2022||Stamford, Connecticut, United States|
|$100M||01 Sep 2022||Israel, North District, Israel|
|$75M||03 Aug 2022||New York, New York, United States|
|$40M||28 Jun 2022||Aurora, Colorado, United States|
– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
– Emulate, Inc. announced the close of an $82m Series E financing round.
– The round was led by Northpond Ventures with additional participation from Perceptive Advisors.
– With this investment, Emulate has raised nearly $225m to date.
– Emulate develops and manufactures next-generation in vitro models that enable researchers to replicate and study human biology and disease, helping them understand and predict drug response with greater precision and detail than possible with conventional cell culture or animal-based methods.
– Organ-on-a-chip technology by Emulate provides flexible microenvironments containing tiny hollow channels lined with living cells and tissues that can be subjected to mechanical forces that mirror breathing or digestion in the human body.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.